Dr. Nishi Suryavanshi Receives Award from ACTG Network

Date: 01/07/2022

Congratulations, Nishi Suryavanshi, recipient of ACTG’s Tuberculosis Transformative Science Group Special Contributions Award.

This is a Phase I, multi-site, open-label, non-comparative study of the PK, safety, tolerability, and acceptability of a...

Rifampin (RIF), the cornerstone of TB treatment, has very problematic drug-drug interactions with PIs. The use of relatively...

This study is currently on hold. The study is designed to characterize the pharmacokinetics of DLM using a model-based...

The purpose of this study is to develop and assess the efficacy of an integrated strategy that includes feasible and scalable...

An estimated 3 million HIV-infected individuals will enter programs for antiretroviral (ARV) treatment in the coming year, with...